Response to the Role of Patient and Drug-Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System

The document discusses the findings of Gupta et al. regarding the incidence of pericardial effusions in patients using oral minoxidil, particularly for alopecia. The study found a 1.27% incidence rate of pericardial effusions, with a dose-independent relationship during oral minoxidil use. Notably, only 6.7% of these cases were reported in patients using the drug for alopecia. The authors highlight the lack of standardized guidelines for monitoring cardiovascular risks in alopecia patients using oral minoxidil, unlike its use in hypertension management, which has established protocols. They suggest that the absence of routine cardiac imaging and baseline measurements may lead to underreporting of pericardial effusions. The document calls for a collaborative approach between specialties to develop standardized guidelines and enhance monitoring to prevent adverse events and improve treatment efficacy for alopecia.